GRK2 as a novel gene therapy target in heart failure.

[1]  W. Koch,et al.  Comparative Cardiac Gene Delivery of Adeno‐Associated Virus Serotypes 1–9 reveals that AAV6 Mediates the Most Efficient Transduction in Mouse Heart , 2010, Clinical and translational science.

[2]  G. Dorn,et al.  Reduction of Sympathetic Activity via Adrenal-targeted GRK2 Gene Deletion Attenuates Heart Failure Progression and Improves Cardiac Function after Myocardial Infarction* , 2010, The Journal of Biological Chemistry.

[3]  D. Leosco,et al.  Adrenal GRK2 lowering is an underlying mechanism for the beneficial sympathetic effects of exercise training in heart failure. , 2010, American journal of physiology. Heart and circulatory physiology.

[4]  W. Koch,et al.  Dynamic Changes in Lymphocyte GRK2 Levels in Cardiac Transplant Patients: A Biomarker for Left Ventricular Function , 2010, Clinical and translational science.

[5]  D. Mancini,et al.  Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial. , 2009, Journal of cardiac failure.

[6]  W. Koch,et al.  Myocardial Adeno-Associated Virus Serotype 6–&bgr;ARKct Gene Therapy Improves Cardiac Function and Normalizes the Neurohormonal Axis in Chronic Heart Failure , 2009, Circulation.

[7]  David M. Harris,et al.  Uncovering G protein-coupled receptor kinase-5 as a histone deacetylase kinase in the nucleus of cardiomyocytes , 2008, Proceedings of the National Academy of Sciences.

[8]  S. Houser,et al.  G Protein-Coupled Receptor Kinase 2 Ablation in Cardiac Myocytes Before or After Myocardial Infarction Prevents Heart Failure , 2008, Circulation research.

[9]  W. Koch,et al.  Gene therapy in heart failure. , 2008, Circulation research.

[10]  Yoshiaki Kawase,et al.  Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure. , 2008, Journal of cardiac failure.

[11]  J. Rabinowitz,et al.  Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[12]  W. Koch,et al.  Modulation of adrenal catecholamine secretion by in vivo gene transfer and manipulation of G protein-coupled receptor kinase-2 activity. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

[13]  W. Koch,et al.  Adrenal adrenoceptors in heart failure: fine-tuning cardiac stimulation. , 2007, Trends in molecular medicine.

[14]  M. Gao,et al.  New signaling pathways associated with increased cardiac adenylyl cyclase 6 expression: implications for possible congestive heart failure therapy. , 2007, Trends in cardiovascular medicine.

[15]  A. Remppis,et al.  Stable Myocardial-Specific AAV6-S100A1 Gene Therapy Results in Chronic Functional Heart Failure Rescue , 2007, Circulation.

[16]  W. Koch,et al.  Adrenal GRK2 upregulation mediates sympathetic overdrive in heart failure , 2007, Nature Medicine.

[17]  G. Dorn,et al.  Cardiac-Specific Ablation of G-Protein Receptor Kinase 2 Redefines Its Roles in Heart Development and &bgr;-Adrenergic Signaling , 2006, Circulation research.

[18]  W. Koch,et al.  Lymphocyte levels of GRK2 (betaARK1) mirror changes in the LVAD-supported failing human heart: lower GRK2 associated with improved beta-adrenergic signaling after mechanical unloading. , 2006, Journal of cardiac failure.

[19]  W. Koch,et al.  Acute ischemic cardiac dysfunction is attenuated via gene transfer of a peptide inhibitor of the β‐adrenergic receptor kinase (βARK1) , 2005 .

[20]  D. Leosco,et al.  Elevated myocardial and lymphocyte GRK2 expression and activity in human heart failure. , 2005, European heart journal.

[21]  Andrew N. Carr,et al.  Enhancement of Cardiac Function and Suppression of Heart Failure Progression By Inhibition of Protein Phosphatase 1 , 2005, Circulation research.

[22]  N. Dalton,et al.  Intracoronary Adenovirus Encoding Adenylyl Cyclase VI Increases Left Ventricular Function in Heart Failure , 2004, Circulation.

[23]  N. Dzimiri,et al.  Differential functional expression of human myocardial G protein receptor kinases in left ventricular cardiac diseases. , 2004, European journal of pharmacology.

[24]  W. Koch,et al.  Targeted &bgr;-Adrenergic Receptor Kinase (&bgr;ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .

[25]  S. Emani,et al.  Right ventricular targeted gene transfer of a beta-adrenergic receptor kinase inhibitor improves ventricular performance after pulmonary artery banding. , 2004, The Journal of thoracic and cardiovascular surgery.

[26]  W. Koch,et al.  Viral-based myocardial gene therapy approaches to alter cardiac function. , 2004, Annual review of physiology.

[27]  W. Koch,et al.  Targeted (cid:1) -Adrenergic Receptor Kinase ( (cid:1) ARK1) Inhibition by Gene Transfer in Failing Human Hearts , 2004 .

[28]  W. Koch,et al.  The β-adrenergic receptor kinase in heart failure , 2003 .

[29]  G. Nagy,et al.  Differential control of adrenal and sympathetic catecholamine release by alpha 2-adrenoceptor subtypes. , 2003, Molecular endocrinology.

[30]  R. Lefkowitz,et al.  Inhibition of βARK1 restores impaired biochemical β-adrenergic receptor responsiveness but does not rescue CREBA133 induced cardiomyopathy , 2002 .

[31]  A. Gerdes,et al.  Myocyte Redistribution of GRK2 and GRK5 in Hypertensive, Heart-Failure–Prone Rats , 2002, Hypertension.

[32]  Harvard Medical School,et al.  Targeting Phospholamban by Gene Transfer in Human Heart Failure , 2002, Circulation.

[33]  M. Caron,et al.  Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and ß-arrestin proteins , 2002, Progress in Neurobiology.

[34]  Robert J. Lefkowitz,et al.  Seven-transmembrane-spanning receptors and heart function , 2002, Nature.

[35]  R. Lefkowitz,et al.  Signalling: Seven-transmembrane receptors , 2002, Nature Reviews Molecular Cell Biology.

[36]  S. Emani,et al.  Right ventricular gene therapy with a beta-adrenergic receptor kinase inhibitor improves survival after pulmonary artery banding. , 2001, The Annals of thoracic surgery.

[37]  W. Koch,et al.  Ventricular Dysfunction After Cardioplegic Arrest Is Improved After Myocardial Gene Transfer of a &bgr;-Adrenergic Receptor Kinase Inhibitor , 2001, Circulation.

[38]  C. Scorer,et al.  Expression of GRK2 is increased in the left ventricles of cardiomyopathic hamsters , 2001, Basic Research in Cardiology.

[39]  R. Lefkowitz,et al.  Cardiac βARK1 inhibition prolongs survival and augments β blocker therapy in a mouse model of severe heart failure , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[40]  L. Leinwand,et al.  Alterations in cardiac adrenergic signaling and calcium cycling differentially affect the progression of cardiomyopathy. , 2001, The Journal of clinical investigation.

[41]  S. Emani,et al.  In Vivo Ventricular Gene Delivery of a &bgr;-Adrenergic Receptor Kinase Inhibitor to the Failing Heart Reverses Cardiac Dysfunction , 2001, Circulation.

[42]  B. Kobilka,et al.  Dual modulation of cell survival and cell death by beta(2)-adrenergic signaling in adult mouse cardiac myocytes. , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[43]  C. Dellorusso,et al.  In vivo acceleration of heart relaxation performance by parvalbumin gene delivery. , 2001, The Journal of clinical investigation.

[44]  E. Lakatta,et al.  The β2-Adrenergic receptor delivers an antiapoptotic signal to cardiac myocytes through Gi-Dependent coupling to phosphatidylinositol 3'-kinase , 2000 .

[45]  R. Lefkowitz,et al.  Preservation of myocardial β-adrenergic receptor signaling delays the development of heart failure after myocardial infarction , 2000 .

[46]  M. Bristow.  β-Adrenergic Receptor Blockade in Chronic Heart Failure , 2000 .

[47]  Catherine Communal,et al.  Opposing Effects of β1- and β2-Adrenergic Receptors on Cardiac Myocyte Apoptosis Role of a Pertussis Toxin–Sensitive G Protein , 1999 .

[48]  K. Propert,et al.  Immune responses to adenovirus and adeno-associated virus in humans , 1999, Gene Therapy.

[49]  R. Lefkowitz,et al.  In Vivo Inhibition of Elevated Myocardial β-Adrenergic Receptor Kinase Activity in Hybrid Transgenic Mice Restores Normal β-Adrenergic Signaling and Function , 1999 .

[50]  G. Dorn,et al.  Low- and high-level transgenic expression of β2-adrenergic receptors differentially affect cardiac hypertrophy and function in Gαq-overexpressing mice , 1999 .

[51]  R. Lefkowitz,et al.  Reciprocal in vivo regulation of myocardial G protein-coupled receptor kinase expression by beta-adrenergic receptor stimulation and blockade. , 1998, Circulation.

[52]  Marc G. Caron,et al.  Control of Myocardial Contractile Function by the Level of β-Adrenergic Receptor Kinase 1 in Gene-targeted Mice* , 1998, The Journal of Biological Chemistry.

[53]  J. Ross,et al.  Expression of a beta-adrenergic receptor kinase 1 inhibitor prevents the development of myocardial failure in gene-targeted mice. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[54]  R. Lefkowitz,et al.  Restoration of beta-adrenergic signaling in failing cardiac ventricular myocytes via adenoviral-mediated gene transfer. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[55]  W. Koch,et al.  Mechanism of β-Adrenergic Receptor Desensitization in Cardiac Hypertrophy Is Increased β-Adrenergic Receptor Kinase* , 1997, The Journal of Biological Chemistry.

[56]  J. Benovic,et al.  G-protein-coupled receptor kinase activity is increased in hypertension. , 1997, The Journal of clinical investigation.

[57]  M. Drazner,et al.  Potentiation of beta-adrenergic signaling by adenoviral-mediated gene transfer in adult rabbit ventricular myocytes. , 1997, The Journal of clinical investigation.

[58]  D. Clapham,et al.  G PROTEIN BETA GAMMA SUBUNITS , 1997 .

[59]  M. Caron,et al.  Essential role of beta-adrenergic receptor kinase 1 in cardiac development and function. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[60]  R. Lefkowitz,et al.  Receptor-specific in vivo desensitization by the G protein-coupled receptor kinase-5 in transgenic mice. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[61]  M. Lohse,et al.  Activation of β-Adrenergic Receptor Kinase During Myocardial Ischemia , 1996 .

[62]  R. Lefkowitz,et al.  Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor. , 1995, Science.

[63]  R. Lefkowitz,et al.  Structure and mechanism of the G protein-coupled receptor kinases. , 1993, The Journal of biological chemistry.

[64]  M. Packer,et al.  The development of positive inotropic agents for chronic heart failure: how have we gone astray? , 1993, Journal of the American College of Cardiology.

[65]  M. Böhm,et al.  Altered expression of beta-adrenergic receptor kinase and beta 1-adrenergic receptors in the failing human heart. , 1993, Circulation.

[66]  M. Lohse,et al.  Altered Expression of, ‐Adrenergic Receptor Kinase and 1‐Adrenergic Receptors in the Failing Human Heart , 1993 .

[67]  O. Brodde.  Beta-adrenoceptors in cardiac disease. , 1993, Pharmacology & therapeutics.

[68]  S. Jamieson,et al.  Beta 1- and beta 2-adrenergic-receptor subpopulations in nonfailing and failing human ventricular myocardium: coupling of both receptor subtypes to muscle contraction and selective beta 1-receptor down-regulation in heart failure. , 1986, Circulation research.

[69]  S. Jamieson,et al.  β1‐ and β2‐Adrenergic‐Receptor Subpopulations in Nonfailing and Failing Human Ventricular Myocardium: Coupling of Both Receptor Subtypes to Muscle Contraction and Selective β1‐Receptor Down‐Regulation in Heart Failure , 1986 .

[70]  D C Harrison,et al.  Decreased catecholamine sensitivity and beta-adrenergic-receptor density in failing human hearts. , 1982, The New England journal of medicine.